Department School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine Position Assistant Professor
|Article types||Original article|
|Peer review||Peer reviewed|
|Title||Effectiveness and safety of dabigatran versus warfarin in real-world Japanese patients with atrial fibrillation: A single-center observational study|
|Journal||Formal name：Journal of Arrhythmia|
|Domestic / Foregin||Domestic|
|Publisher||Japanese Heart Rhythm Society|
|Volume, Issue, Page||33(2),107-110頁|
|Author and coauthor||NAGANUMA Miyoko†, SHIGA Tsuyoshi*, NAGAO Takehiko, SUZUKI Atsushi, MURASAKI Kagari, HAGIWARA Nobuhisa|
In "real-world" practice, anticoagulant therapy is indicated for patients whose clinical profiles are not addressed in randomized clinical trials. We assessed the effectiveness and safety of dabigatran versus warfarin in "real-world" Japanese patients with non-valvular atrial fibrillation (NVAF).
Among 613 NVAF patients who initiated dabigatran or warfarin therapy during the period between 2011 and 2013, 362 patients were included in the study after propensity score adjustment. The median follow-up period was 1.3 years. The effectiveness and safety outcomes were thromboembolism and major bleeding, respectively.
The propensity-matched hazard ratios of thromboembolism and major bleeding with dabigatran were 1.03 (95% CI: 0.12-8.04, p=0.971) and 0.15 (95% CI: 0.01-0.90, p=0.037), respectively.
The ability of dabigatran to prevent thromboembolism is comparable to that of warfarin; however, the major bleeding rate is lower with dabigatran in "real-world" NVAF patients.